Login / Signup

Frequency of pharmacogenomic variants affecting efficacy and safety of anti-cancer drugs in a south Asian population from Sri Lanka.

Priyanga RanasingheNirmala Dushyanthi SirisenaThuwaragesh VishnukanthanJeremy N AriaduraiSathsarani ThilakarathneC D Nelanka PriyadarshaniD P Bhagya HendalageVajira H W Dissanayake
Published in: BMC medical genomics (2024)
Sri Lankans are likely to show lower toxicity risk with sorafenib (rs7557402 c.84,131 C > G) and, higher toxicity risk with fluoropyrimidines (rs56038477 c.1236G > A) and mercaptopurine (rs116855232 c.415 C > T), and reduced effectiveness with tamoxifen (rs1065852 c.100 C > T) and platinum compounds (rs25487). These findings highlight the potential contribution of these genetic variations to the individual variability in anti-cancer dosage requirements among Sri Lankans.
Keyphrases
  • randomized controlled trial
  • systematic review
  • copy number
  • gene expression
  • genome wide
  • dna methylation
  • estrogen receptor
  • human health